BMS-983970 manufacturers
- BMS-983970
-
- $198.00
-
2026-07-27
- CAS:1584713-87-0
- Purity:
- Supply Ability: 10g
- BMS-983970
-
- $198.00
-
2026-07-27
- CAS:1584713-87-0
- Purity:
- Supply Ability: 10g
- BMS-983970
-
- $198.00
-
2025-07-25
- CAS:1584713-87-0
- Purity:
- Supply Ability: 10g
|
| | BMS-983970 Basic information |
| Product Name: | BMS-983970 | | Synonyms: | BMS-983970;Butanediamide, 3-(cyclopropylmethyl)-N1-[(3S)-9-fluoro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(3,3,3-trifluoropropyl)-, (2R,3S)-;BMS983970,BMS 983970 | | CAS: | 1584713-87-0 | | MF: | C26H26F4N4O3 | | MW: | 518.5 | | EINECS: | | | Product Categories: | | | Mol File: | 1584713-87-0.mol |  |
| | BMS-983970 Chemical Properties |
| Boiling point | 730.2±60.0 °C(Predicted) | | density | 1.45±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 50 mg/mL (96.43 mM); Water: < 0.1 mg/mL (insoluble) | | pka | 10.57±0.70(Predicted) | | form | Powder | | color | White to off-white |
| | BMS-983970 Usage And Synthesis |
| Uses | BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers[1]. | | in vivo | BMS-983970 demonstrates anti-tumor activity in T-cell acute lymphoblastic leukemia (T-ALL) and solid tumor xenograft models[1]. | | References | [1] Ashvinikumar V. Gavai, et al. Abstract 1643: BMS-983970, an oral pan-Notch inhibitor for the treatment of cancer. Cancer Res October 1, 2014 74; 1643. |
| | BMS-983970 Preparation Products And Raw materials |
|